Hyperacidity, GERD, and ulcers:
Indications for Famotidine Injection Preservative-Free:
Hospitalized patients with pathological hypersecretory conditions, intractable ulcers, or as a short-term alternative to oral dosage forms.
Give by IV inj over 2 mins or infuse over 15–30 mins. 20mg every 12hrs.
See full labeling. Give by IV inj over 2 mins or infuse over 15 mins. <1yr: not recommended. 1–16yrs: initially 0.25mg/kg every 12hrs; max 40mg/day.
History of serious hypersensitivity reactions to H2 receptor antagonists.
Symptomatic response does not preclude gastric malignancy; evaluate prior to initiation. Moderate to severe renal impairment (CrCl <50mL/min): reduce to ½ the dose or prolong dosing interval to 36–48hrs. Elderly: use low doses. Pregnancy. Nursing mothers.
Concomitant dasatinib, delavirdine mesylate, cefditoren, fosamprenavir: not recommended. May alter absorption of pH-dependent drugs (eg, atazanavir, erlotinib, ketoconazole, itraconazole, ledipasvir/sofosbuvir, nilotinib, rilpivirine). May potentiate CYP1A2 substrates (eg, tizanidine); avoid; if necessary, monitor for hypotension, bradycardia, drowsiness. May give antacids concomitantly.
Headache, dizziness, constipation, diarrhea, inj site reactions; rare: CNS reactions, prolonged QT interval in renal impairment (moderate and severe).
Formerly known under the brand name Pepcid Injection.
Tabs—30, 100; Susp—50mL; Inj—contact supplier